Literature DB >> 31794434

Chikungunya virus replication in skeletal muscle cells is required for disease development.

Anthony J Lentscher1,2, Mary K McCarthy3, Nicholas A May3, Bennett J Davenport3, Stephanie A Montgomery4, Krishnan Raghunathan2,5, Nicole McAllister1,2, Laurie A Silva2,5, Thomas E Morrison3, Terence S Dermody1,2,5.   

Abstract

Chikungunya virus (CHIKV) is an arbovirus capable of causing a severe and often debilitating rheumatic syndrome in humans. CHIKV replicates in a wide variety of cell types in mammals, which has made attributing pathologic outcomes to replication at specific sites difficult. To assess the contribution of CHIKV replication in skeletal muscle cells to pathogenesis, we engineered a CHIKV strain exhibiting restricted replication in these cells via incorporation of target sequences for skeletal muscle cell-specific miR-206. This virus, which we term SKE, displayed diminished replication in skeletal muscle cells in a mouse model of CHIKV disease. Mice infected with SKE developed less severe disease signs, including diminished swelling in the inoculated foot and less necrosis and inflammation in the interosseous muscles. SKE infection was associated with diminished infiltration of T cells into the interosseous muscle as well as decreased production of Il1b, Il6, Ip10, and Tnfa transcripts. Importantly, blockade of the IL-6 receptor led to diminished swelling of a control CHIKV strain capable of replication in skeletal muscle, reducing swelling to levels observed in mice infected with SKE. These data implicate replication in skeletal muscle cells and release of IL-6 as important mediators of CHIKV disease.

Entities:  

Keywords:  Arthritis; Infectious disease; Muscle; Noncoding RNAs; Virology

Year:  2020        PMID: 31794434      PMCID: PMC7269570          DOI: 10.1172/JCI129893

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

1.  The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic.

Authors:  R W ROSS
Journal:  J Hyg (Lond)       Date:  1956-06

2.  A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Authors:  Thomas E Morrison; Lauren Oko; Stephanie A Montgomery; Alan C Whitmore; Alina R Lotstein; Bronwyn M Gunn; Susan A Elmore; Mark T Heise
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Chikungunya in the Americas.

Authors:  Isabelle Leparc-Goffart; Antoine Nougairede; Sylvie Cassadou; Christine Prat; Xavier de Lamballerie
Journal:  Lancet       Date:  2014-02-08       Impact factor: 79.321

4.  Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice.

Authors:  Feng He; Hailan Yao; Jianmin Wang; Zonghui Xiao; Le Xin; Zhuo Liu; Xiaolin Ma; Juan Sun; Qi Jin; Zhewei Liu
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

5.  The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice.

Authors:  R A Collins; M D Grounds
Journal:  J Histochem Cytochem       Date:  2001-08       Impact factor: 2.479

6.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

7.  Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo.

Authors:  M Saito; K Yoshida; M Hibi; T Taga; T Kishimoto
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

8.  Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Authors:  Pankaj Pal; Kimberly A Dowd; James D Brien; Melissa A Edeling; Sergey Gorlatov; Syd Johnson; Iris Lee; Wataru Akahata; Gary J Nabel; Mareike K S Richter; Jolanda M Smit; Daved H Fremont; Theodore C Pierson; Mark T Heise; Michael S Diamond
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

9.  Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate.

Authors:  Kenneth S Plante; Shannan L Rossi; Nicholas A Bergren; Robert L Seymour; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2015-09-04

10.  Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues.

Authors:  Zhiyun Guo; Miranda Maki; Ruofan Ding; Yalan Yang; Bao Zhang; Lili Xiong
Journal:  Sci Rep       Date:  2014-06-03       Impact factor: 4.379

View more
  9 in total

1.  Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle.

Authors:  Anne Moscona
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

2.  Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.

Authors:  Marissa C Locke; Lindsey E Fox; Bria F Dunlap; Alissa R Young; Kristen Monte; Deborah J Lenschow
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

3.  A Critical Role for STING Signaling in Limiting Pathogenesis of Chikungunya Virus.

Authors:  Tingting Geng; Tao Lin; Duomeng Yang; Andrew G Harrison; Anthony T Vella; Erol Fikrig; Penghua Wang
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

4.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

5.  In vitro and in vivo studies reveal α-Mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus.

Authors:  Poonam Patil; Megha Agrawal; Shahdab Almelkar; Manish Kumar Jeengar; Ashwini More; Kalichamy Alagarasu; Naveen V Kumar; Prathama S Mainkar; Deepti Parashar; Sarah Cherian
Journal:  Virol J       Date:  2021-02-28       Impact factor: 4.099

6.  Malaria abrogates O'nyong-nyong virus pathologies by restricting virus infection in nonimmune cells.

Authors:  Anthony Torres-Ruesta; Teck-Hui Teo; Yi-Hao Chan; Siti Naqiah Amrun; Nicholas Kim-Wah Yeo; Cheryl Yi-Pin Lee; Samantha Yee-Teng Nguee; Matthew Zirui Tay; Francois Nosten; Siew-Wai Fong; Fok-Moon Lum; Guillaume Carissimo; Laurent Renia; Lisa Fp Ng
Journal:  Life Sci Alliance       Date:  2022-01-17

Review 7.  Unraveling Muscle Impairment Associated With COVID-19 and the Role of 3D Culture in Its Investigation.

Authors:  Maria Luiza G A Seixas; Lucas Pari Mitre; Shahin Shams; Gabriel Barbugian Lanzuolo; Cynthia Silva Bartolomeo; Eduardo A Silva; Carla Maximo Prado; Rodrigo Ureshino; Roberta Sessa Stilhano
Journal:  Front Nutr       Date:  2022-02-10

Review 8.  The regenerative potential of Pax3/Pax7 on skeletal muscle injury.

Authors:  Muhamad Azhar; Bantari Wisynu Kusuma Wardhani; Editha Renesteen
Journal:  J Genet Eng Biotechnol       Date:  2022-10-17

Review 9.  Arboviruses and Muscle Disorders: From Disease to Cell Biology.

Authors:  Claudia Filippone; Vincent Legros; Patricia Jeannin; Valérie Choumet; Gillian Butler-Browne; Jim Zoladek; Vincent Mouly; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  Viruses       Date:  2020-06-05       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.